November 21, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) --…
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…